Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$2.54 USD
+0.10 (4.10%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.54 USD
+0.10 (4.10%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug
by Zacks Equity Research
The FDA clears TC BioPharm's (TCBP) investigational new drug application seeking approval to begin a clinical study on its pipeline candidate, TCB008, for treating acute myeloid leukemia. Stock declines.
GSK's Blenrep Combo Meets PFS Endpoint in Head-to-Head Study
by Zacks Equity Research
GSK announces positive data from the DREAMM-7 head-to-head phase III study evaluating Blenrep for second-line treatment of relapsed or refractory multiple myeloma. The study meets its primary endpoint.
Freeline (FRLN) Shares Rise on Merger Agreement With Syncona
by Zacks Equity Research
Freeline Therapeutics (FRLN) is set to be acquired by Syncona Ltd. The transaction is expected to be closed in the first quarter of 2024. Shares rise.
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down
by Zacks Equity Research
The FDA clears Immix's (IMMX) investigational new drug application for BCMA CAR-T cell therapy, NXC-201, to expand clinical studies in relapsed/refractory AL amyloidosis to the United States. Stock falls.
Here's Why You May Invest in Puma Biotechnology (PBYI) Stock
by Zacks Equity Research
Here, we discuss some reasons why investing in Puma Biotechnology (PBYI) stock now may turn out to be a more prudent move than ever.
PBYI vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBYI vs. TECH: Which Stock Is the Better Value Option?
SpringWorks (SWTX) Falls Despite Positive Mirdametinib Study Data
by Zacks Equity Research
SpringWorks (SWTX) posts encouraging data from phase IIb study on its MEK inhibitor, mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas. Stock falls.
Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC
by Zacks Equity Research
The FDA bestows Fast Track designation to Chemomab's (CMMB) pipeline candidate, CM-101, for the treatment of primary sclerosing cholangitis. Stock rises.
Puma Biotech (PBYI) Q3 Earnings Beat, Revenues Lag Estimates
by Zacks Equity Research
Puma Biotech's (PBYI) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens the full-year revenue guidance.
Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales
by Zacks Equity Research
Agios' (AGIO) Q3 earnings beat estimates, but sales miss the same.
Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss
by Zacks Equity Research
Karuna's (KRTX) third-quarter 2023 earnings miss estimates. The company did not record any sales during the quarter.
Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the same. Management reiterated its previously issued financial guidance for 2023.
Puma Biotech (PBYI) Tops Q3 Earnings Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 13.33% and 3.16%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
PBYI or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBYI vs. TECH: Which Stock Is the Better Value Option?
Puma Biotech (PBYI) Loses -18.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Puma Biotech (PBYI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
PBYI vs. AMGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBYI vs. AMGN: Which Stock Is the Better Value Option?
Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC
by Zacks Equity Research
Puma's (PBYI) alisertib receives the Orphan Drug designation from the FDA for treating patients with small cell lung cancer.
Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform
by Zacks Equity Research
Puma Biotechnology (PBYI) beats second-quarter earnings and sales estimates. Stock rises in after-hours.
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 42.86% and 6.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PBYI vs. GMAB: Which Stock Is the Better Value Option?
5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND, MESO and PBYI well amid volatility.
Bluebird (BLUE) Down 26% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PBYI or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBYI vs. TECH: Which Stock Is the Better Value Option?
Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now
by Zacks Equity Research
Puma Biotechnology (PBYI), a top-ranked stock, has a promising development candidate, alisertib. Its only marketed product, Nerlynx (neratinib), is witnessing improving demand trends in the United States.
PBYI vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBYI vs. TECH: Which Stock Is the Better Value Option?